Search clinical trials for: AZD2171

Total 201 results

AstraZeneca

Completed

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Renal Cell Carcinoma

United Kingdom, Netherlands
Erasmus Medical Center
Sanofi

Withdrawn

INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION)

Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric Cancer

Netherlands
National Cancer Institute (NCI)

Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Acute Myelogenous Leukemia | Refractory or Recurrent Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
AstraZeneca

Completed

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United Kingdom
Radboud University Medical Center

Terminated

Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion

Malignant Ascites | Malignant Pleural Effusion

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Renal Cell Cancer | Stage IV Non-small Cell Lung Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer | Tumors Metastatic to Brain

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid (PET)

Alzheimer´s Disease

Sweden
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Xuanwu Hospital, Beijing
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorder
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage... and other conditions

United States
University of Washington
AstraZeneca

Terminated

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
AstraZeneca

Completed

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Neoplasms

Germany
AstraZeneca

Completed

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Brain Tumor | Recurrent Glioblastoma

United States, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Completed

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Se-Hoon Lee

Terminated

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer (SUKSES-N5)

SCLC, Recurrent

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Ovarian Carcinoma | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Recurrent Non-Small Cell... and other conditions

Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Fallopian Tube Carcinoma | Ovarian Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian...

United States
AstraZeneca

Completed

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Unknown

TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer (TOPARP)

Adenocarcinoma of the Prostate

United Kingdom
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Neoplasm Metastasis

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
AstraZeneca

Completed

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Nociceptive Pain | Peripheral Neuropathic Pain

United Kingdom
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca

Active, not recruiting

Phase I Comparative Bioavailability Study

Solid Tumors

Belgium, United Kingdom, Switzerland, Australia
AstraZeneca
British Columbia Cancer Agency

Completed

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Breast Cancer | Ovarian Carcinoma

Canada
AstraZeneca

Completed

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Advanced Breast Cancer

United States, Australia, Brazil
MedSIR

Terminated

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent (NOBROLA)

Breast Cancer

Spain
University College, London
AstraZeneca

Completed

Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers (ABC-03)

Biliary Tract Neoplasms

United Kingdom
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
National Cancer Institute (NCI)

Completed

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
AstraZeneca

Terminated

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

Japan
Thomas Jefferson University
AstraZeneca

Active, not recruiting

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Recurrent Breast Carcinoma | Metastatic Malignant Neoplasm in the Chest Wall

United States
Lisette Nixon
AstraZeneca

Unknown

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN)

Non-small Cell Lung Cancer

United Kingdom
Dana-Farber Cancer Institute

Withdrawn

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States

Search clinical trials for: AZD2171

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations